Page 166 - Biomarkers for risk stratification and guidance in heart failure
P. 166
REFERENCES
1. Curtis LH, Greiner MA, Hammill BG, et al. Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Archives of internal medicine 2008;168:2481-8.
2. Hartfalen, Kosten. 2015. (Accessed 18-06-2015, at https://www.volksgezondheidenzorg.info/ onderwerp/hartfalen/kosten/kosten - node-kosten-van-zorg-voor-hartfalen.)
3. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72.
4. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100.
5. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. Assessing diagnosis in heart failure: which features are any use? QJM : monthly journal of the Association of Physicians 1997;90:335-9.
6. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, et al. N-terminal probrain natriuretic peptide (NT- proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. European journal of heart failure 2004;6:301-8.
7. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. Journal of the American College of Cardiology 2003;42:728-35.
8. Stiell IG, Clement CM, Brison RJ, et al. A risk scoring system to identify emergency department patients with heart failure at high risk for serious adverse events. Acad Emerg Med 2013;20:17-26.
9. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Archives of internal medicine 2003;163:2345-53.
10. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005;172:1041-6.
11. Shorr AF, Sun X, Johannes RS, Yaitanes A, Tabak YP. Validation of a novel risk score for severity of illness in acute exacerbations of COPD. Chest 2011;140:1177-83.
12. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005;118:384-92.
13. Baggish AL, Lloyd-Jones DM, Blatt J, et al. A clinical and biochemical score for mortality prediction in patients with acute dyspnoea: derivation, validation and incorporation into a bedside programme. Heart 2008;94:1032-7.
14. Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL, Jr. Independent and incremental prognostic
value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in 7 the Emergency Department (PRIDE) study. Clin Chim Acta 2008;392:41-5.
15. Ray P, Birolleau S, Lefort Y, et al. Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis. Critical care 2006;10:R82.
16. Michelson E, Hollrah S. Evaluation of the patient with shortness of breath: an evidence based approach. Emergency medicine clinics of North America 1999;17:221-37, x.
17. Braunwald E. Biomarkers in heart failure. The New England journal of medicine 2008;358:2148-59.
18. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. European heart journal 2006;27:330-7.
19. Peacock WF, Nowak R, Christenson R, et al. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med 2011;18:947-58.
20. van Kimmenade RR, Januzzi JL, Jr., Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. Journal of the American College of Cardiology 2006;48:1217-24.
21. de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012;272:55-64.
22. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. European journal of heart failure 2010;12:826-32.
General Discussion
165
